Breakthrough therapy is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section 902 of the 9 July 2012 Food and Drug Administration Safety and Innovation Act. From Wikipedia
The JAMA study identified 100 micrograms as the optimal MM120 dose, prompting phase 3 testing under FDA Breakthrough status.
